Modality
ERT
MOA
CGRPant
Target
FXIa
Pathway
Complement
HCC
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
~Jul 2021
→ ~Oct 2022
Phase 3
~Jan 2023
→ ~Apr 2024
NDA/BLA
Jul 2024
→ Mar 2028
NDA/BLACurrent
NCT06614062
2,625 pts·HCC
2024-07→2028-03·Terminated
2,625 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-212.0y awayPh3 Readout· HCC
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-03-21 · 2.0y away
HCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06614062 | NDA/BLA | HCC | Terminated | 2625 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |